BACKGROUND Ivosidenib (AG-120, IVO) is a first-in-class oral inhibitor of mutant isocitrate dehyd... more BACKGROUND Ivosidenib (AG-120, IVO) is a first-in-class oral inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), and vorasidenib (AG-881, VOR) is an oral, potent, brain-penetrant inhibitor of mIDH1/2. Both have been evaluated in glioma patients in ongoing phase 1 studies. In orthotopic glioma models, IVO and VOR reduced 2-hydroxyglutarate (2-HG) levels by 85% and 98%, respectively, despite different brain-to-plasma ratios (< 0.04 vs 1.33). METHODS Patients with recurrent, nonenhancing, WHO-2016 grade 2/3, mIDH1-R132H oligodendroglioma or astrocytoma undergoing craniotomy were randomized 2:2:1 to IVO 500mg QD, VOR 50mg QD, or no treatment (cohort 1), or 1:1 to IVO 250mg BID or VOR 10mg QD (cohort 2), for 4 weeks preoperatively. Postoperatively, patients continued receiving IVO or VOR (control patients were randomized 1:1 to IVO or VOR). Tumors were assessed for mIDH1 status, cellularity, and 2-HG and drug concentrations. Treated subjects were compared with controls and mIDH1/w...
Australian & New Zealand Journal of Psychiatry, 2012
Australian & New Zealand Journal of Psychiatry, 46(11) Griffiths EV, Willis J and Spark MJ (2... more Australian & New Zealand Journal of Psychiatry, 46(11) Griffiths EV, Willis J and Spark MJ (2012) A systematic review of psychotropic drug prescribing for prisoners. Australian and New Zealand Journal of Psychiatry 46: 407–421. Morgan RD, Steffan J, Shaw LB, et al. (2007) Needs for and barriers to correctional mental health services: inmate perceptions. Psychiatric Services 58: 1181–1186. Simpson AI, Brinded PM, Fairley N, et al. (2003) Does ethnicity affect need for mental health service among New Zealand prisoners? Australian and New Zealand Journal of Psychiatry 37: 728–734.
BACKGROUND Ivosidenib (AG-120, IVO) is a first-in-class oral inhibitor of mutant isocitrate dehyd... more BACKGROUND Ivosidenib (AG-120, IVO) is a first-in-class oral inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), and vorasidenib (AG-881, VOR) is an oral, potent, brain-penetrant inhibitor of mIDH1/2. Both have been evaluated in glioma patients in ongoing phase 1 studies. In orthotopic glioma models, IVO and VOR reduced 2-hydroxyglutarate (2-HG) levels by 85% and 98%, respectively, despite different brain-to-plasma ratios (< 0.04 vs 1.33). METHODS Patients with recurrent, nonenhancing, WHO-2016 grade 2/3, mIDH1-R132H oligodendroglioma or astrocytoma undergoing craniotomy were randomized 2:2:1 to IVO 500mg QD, VOR 50mg QD, or no treatment (cohort 1), or 1:1 to IVO 250mg BID or VOR 10mg QD (cohort 2), for 4 weeks preoperatively. Postoperatively, patients continued receiving IVO or VOR (control patients were randomized 1:1 to IVO or VOR). Tumors were assessed for mIDH1 status, cellularity, and 2-HG and drug concentrations. Treated subjects were compared with controls and mIDH1/w...
Australian & New Zealand Journal of Psychiatry, 2012
Australian & New Zealand Journal of Psychiatry, 46(11) Griffiths EV, Willis J and Spark MJ (2... more Australian & New Zealand Journal of Psychiatry, 46(11) Griffiths EV, Willis J and Spark MJ (2012) A systematic review of psychotropic drug prescribing for prisoners. Australian and New Zealand Journal of Psychiatry 46: 407–421. Morgan RD, Steffan J, Shaw LB, et al. (2007) Needs for and barriers to correctional mental health services: inmate perceptions. Psychiatric Services 58: 1181–1186. Simpson AI, Brinded PM, Fairley N, et al. (2003) Does ethnicity affect need for mental health service among New Zealand prisoners? Australian and New Zealand Journal of Psychiatry 37: 728–734.
Uploads
Papers by Islam Hassan